CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Off-Label Use of Intravenous Immunoglobulin: A Review of Clinical Effectiveness

Last updated: November 1, 2017
Project Number: RC0976-000 - RD0042-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report


  1. What is the clinical effectiveness of IVIG for off-label uses?

Key Message

Results in some studies suggested that IVIG reduced all-cause mortality in patients with sepsis or septic shock, but the quality of evidence for both adults and neonates was considered low. Whereas the findings in other studies failed to demonstrate that IVIG had a statistically significant impact on these patient populations. There was insufficient evidence to assess the effectiveness of IVIG used to treat patients with Alzheimer’s disease, bone marrow or stem cell transplantation, epilepsy, or influenza.